GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: GSK1322322
Compound class:
Synthetic organic
Comment: Lanopepden is a first-in-class antibacterial that targets peptide deformylase (PDF), a bacterial enzyme essential for protein maturation [3-4].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Corey R, Naderer OJ, O'Riordan WD, Dumont E, Jones LS, Kurtinecz M, Zhu JZ. (2014)
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother, 58 (11): 6518-27. [PMID:25136015] |
|
2. Hoover JL, Singley CM, Elefante P, DeMarsh P, Zalacain M, Rittenhouse S. (2017)
Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats. Antimicrob Agents Chemother, 61 (11). [PMID:28807913] |
|
3. Min S, Ingraham K, Huang J, McCloskey L, Rilling S, Windau A, Pizzollo J, Butler D, Aubart K, Miller LA et al.. (2015)
Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae. Antimicrob Agents Chemother, 59 (8): 4644-52. [PMID:26014938] |
|
4. O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D. (2013)
Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob Agents Chemother, 57 (5): 2333-42. [PMID:23478958] |